Yahoo Finance Today’s Research Reports on Stocks to Watch: Arrowhead Pharmaceuticals and ZIOPHARM Oncology
NEW YORK, NY / ACCESSWIRE / June 19, 2018 / Arrowhead Pharmaceuticals was seeing big gains in Monday's trading session after announcing that it has fully enrolled its phase 1 study of ARO-AAT, for alpha-1 antitrypsin deficiency (AATD). Shares of ZIOPHARM were dragging over 18% by the close after the FDA put a hold on its phase 1 study to evaluate CD19-specific CAR-T therapies.
RDI Initiates Coverage on:
Arrowhead Pharmaceuticals, Inc.
https://rdinvesting.com/news/?ticker=ARWR
ZIOPHARM Oncology, Inc.
https://rdinvesting.com/news/?ticker=ZIOP
Arrowhead Pharmaceuticals, Inc. shares closed up a little over 24% on about 5.5 million shares traded yesterday. The stock hit a brand new high of $14.00 on Monday after the company said it has fully enrolled its phase 1 study of ARO-AAT, the company's second generation subcutaneously administered RNA interference (RNAi) therapeutic being developed as a treatment for a rare genetic liver disease associated with alpha-1 antitrypsin deficiency called AATD. The company's CEO and President, Chris Anzalone, Ph.D., stated, "The ARO-AAT Phase 1 study provides the first readout on pharmacologic activity for a therapeutic leveraging our proprietary Targeted RNAi Molecule, or TRiM™, platform. We have escalated above a dose that we believe achieves maximal activity, and all doses to date appear to be generally well-tolerated." Arrowhead Pharmaceuticals is expecting to submit a late-breaking abstract with initial clinical data on ARO-AAT to the Liver Meeting®, the Annual Meeting of the American Association for the Study of Liver Disease (AASLD), this November.
Access RDI's Arrowhead Pharmaceuticals, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=ARWR
ZIOPHARM Oncology, Inc. shares closed down a little over 18% yesterday on about 5 million shares traded. The stock came just 6 cents shy of its 52-week low on Monday after announcing that the Food and Drug Administration has asked for more information before signing off on a phase 1 study of the company's "Sleeping Beauty" CAR-T for leukemia and lymphoma. The Phase 1 trial to evaluate CD19-specific CAR-T therapies manufactured under point-of-care has been placed on hold. The company's Chief Executive Officer Laurence Cooper, M.D., Ph.D stated, "We know what is needed to address the hold issues and are looking forward to responding to the agency in a timely manner. We are undertaking cutting-edge science and are on the verge of a paradigm shift based on our approach to very-rapidly manufacture CD19-specific T cells within two days using our non-viral approach to CAR-T therapy based on the Sleeping Beauty platform."
Access RDI's ZIOPHARM Oncology, Inc. Research Report at:
https://rdinvesting.com/news/?ticker=ZIOP
Our Actionable Research on Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) and ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
Email:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: RDInvesting.com
